-葡萄糖共运输体2抑制剂在肝脏疾病中的作用
Prajna Anirvan1, Suprabhat Giri2, Sayan Malakar3
1Department of Gastroenterology, Institute of Medical Sciences and SUM Hospital Campus II, Bhubaneswar 754001, Odisha, India.
World journal of experimental medicine
|January 7, 2026
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂,最初用于糖尿病,对肝脏疾病有希望. 它们可以减少脂肪肝疾病,帮助肝硬化管理,并有助于预防肝癌.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂降低了脏中的葡萄糖再吸收.
- 它们最初是针对糖尿病开发的,现在正在研究它们的额外血糖效应.
- 新出现的证据表明,SGLT2抑制剂会影响肝脏健康.
研究的目的:
- 审查SGLT2抑制剂在治疗肝脏疾病中的多方面的作用.
- 阐明它们在治疗脂肪肝,肝硬化和预防肝细胞癌 (HCC) 的潜力.
主要方法:
- 关于SGLT2抑制剂和肝病的文学综合研究.
- 分析调节氧化应激,炎症和自的机制.
- 对肝硬化和HCC患者的临床结果的评估.
主要成果:
- SGLT2 抑制剂可能会降低代谢功能障碍相关的肥胖性肝病中的肥胖症和炎症.
- 它们显示出在治疗抗利尿剂炎和降低肝硬化死亡率方面的潜力.
- 有证据表明,它在调节HCC路径和改善患者存活率方面发挥着作用.
结论:
- 对于各种肝脏疾病,SGLT2抑制剂提供了超出血糖控制的潜在治疗益处.
- 需要进一步的研究来充分确定它们在肝病学中的有效性和安全性.
- 这些药物代表了管理复杂肝病的有希望的途径.
相关概念视频
Secondary Active Transport
136.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.8K
Secondary Active Transport
9.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.3K
Glucose Absorption Into the Small Intestine
34.9K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.9K
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581


